Vericel Corporation (VCEL)
Vericel Corporation (VCEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Vericel Corporation (VCEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Vericel: MACI And Regenerative Knee Cartilage
Vericel's MACI already has an established commercial base, which I think gives them an easier path for future growth. MACI's arthroscopic delivery could also help it expand among surgeons. That's why VCEL's Burlington added capacity is timely if demand indeed increases. I also like that VCEL's recently gained BARDA contract helps with its Burn Care business. VCEL also has a potential UK launch and an ankle indication in the works.
Vericel Q2 Earnings Call Highlights
Vericel NASDAQ: VCEL reported record second-quarter revenue and raised its full-year outlook, citing continued growth in its MACI cartilage repair franchise and Burn Care business, along with improved profitability and cash generation.
Vericel Corporation (VCEL) Q2 2026 Earnings Call Transcript
Vericel Corporation (VCEL) Q2 2026 Earnings Call Transcript
Vericel Corporation (VCEL) Beats Q2 Earnings and Revenue Estimates
Vericel Corporation (VCEL) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to a loss of $0.01 per share a year ago.
Vericel Q1 Earnings Call Highlights
Vericel NASDAQ: VCEL reported record first-quarter revenue and raised its full-year 2026 outlook, citing strong growth across its MACI cartilage repair franchise and Burn Care business, as well as expected NexoBrid procurement revenue from a new federal contract.
Vericel Corporation (VCEL) Q1 2026 Earnings Call Transcript
Vericel Corporation (VCEL) Q1 2026 Earnings Call Transcript
Vericel Corporation (VCEL) Reports Q1 Loss, Beats Revenue Estimates
Vericel Corporation (VCEL) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.23 per share a year ago.
Wall Street Analysts Think Vericel (VCEL) Could Surge 53.42%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 53.4% in Vericel (VCEL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Vericel Corporation (VCEL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Vericel Corporation (VCEL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Vericel Corporation (VCEL) Q3 Earnings and Revenues Top Estimates
Vericel Corporation (VCEL) came out with quarterly earnings of $0.1 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to a loss of $0.02 per share a year ago.
Vericel Corporation (VCEL) Reports Q2 Loss, Lags Revenue Estimates
Vericel Corporation (VCEL) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to a loss of $0.1 per share a year ago.
